Search Site

Bristol-Myers Squibb

Investors: Brace for a Turbulent Second Quarter

Fasten your seat belts. The second quarter is expected to be a bumpy ride.After a volatile first quarter for stocks that ended with the S&P 500 advancing a measly 1.3%, the broad-market index kicked off the second quarter on a high note. But experts forecast the second quarter will bring more volatility and possibly a long-awaited correction."I'll go out on a limb and say I think [the correction] starts this quarter," said Uri Landesman, president of Platinum Partners, a NY-based hedge fund."I'm not calling the end of the bull market. I still think we'll see 2000 on the S&P 500 by the end of the year, first quarter of next year, but I think you could see 1600 first." The S&P 500 recently traded at about 1860.It's been 30 months since the market declined 10% or more. But this quarter could break the trend if history is any guide. Data going back to 1945 show the S&P 500 posted its worst performance of the entire four-year presidential cycle during the second quarter of a mid-term electi...

Read More

  1. Stock Futures Slide as Emerging-Market Fears Swell

    Wall Street was setting up for an bumpy open as stock futures pushed lower on Friday, looking set to extend sharp losses logged the prior session after several Asian...

  2. A golden era for growth

    Lord Abbett director Thomas O’Halloran on how to beat the market.

  3. AstraZeneca Forecasts Faster Return To Growth

    AstraZeneca expects new drugs and a recent diabetes deal to offset a wave of patent expiries and return it to growth faster than analysts predict, with 2017 revenue ...

  4. Lexicon Pharma Cuts 45% Workforce, CEO to Leave

    Lexicon Pharmaceuticals Inc said its chief executive would leave and it would cut its workforce by about 45 percent, as it moves its focus away from drug discovery t...

  5. Facebook shares lower after secondary offering

    FBN's Tracy Byrnes breaks down afternoon market news.

  6. AstraZeneca to Buy Bristol's Stake in Venture

    AstraZeneca (NYSE:AZN) agreed on Thursday to buy Bristol-Myers Squibb's (NYSE:BMY) stake in their diabetes joint venture for up to $4.1 billion.The London-based biop...

  7. European Stocks Rally After U.S. Fed Tapers

    European stock indexes rallied at the open on Thursday as markets interpreted the U.S. Federal Reserve's taper decision as confidence in the underlying strength in t...

  8. Facebook Shares Slammed, And Other #Stocks2Watch

    Facebook [FB]Facebook took a beating after the social-networking giant revealed a 70-million-share follow-on offering, in which chief executive Mark Zuckerberg will ...

  9. Teva Pharm CEO resigns, CFO stands in on interim basis

    Teva Pharmaceutical Industries , the world's largest generic drugmaker, said its chief executive Jeremy Levin was stepping down and finance chief Eyal Desheh would s...

  10. Bristol-Myers Squibb upgraded at Morgan Stanley

    FBN’s Nicole Petallides with the latest on the market.

  11. Bristol -Myers Lifted To Overweight: Morgan Stanley

    Bristol-Myers Squibb Co. was lifted to an overweight rating from equal-weight on Monday by Morgan Stanley, which also raised its price target to $60 from $45. The up...

  12. Howie Mandel talks hidden cameras, 'America's Got Talent'

    TV star on 'Fox & Friends'

  1. GSK Stops Lung Cancer Vaccine Trial

    GlaxoSmithKline Plc (GSK) has stopped a high-profile clinical trial using a novel vaccine to fight lung cancer after deciding it will not be possible to find a sub-g...

  2. Novo Nordisk Upgraded to 'Buy'

    Novo Nordisk (NYSE:NVO) was handed an upgrade to "buy" from "hold" on Tuesday from Austria's Erste Group, helping to boost its shares 1%.The Denmark-based drug giant...

  3. Pharma, Retail and big banks: Buy, sell or hold?

    United Advisors chief market strategist Scott Martin gives his outlook for the pharmaceuticals, retail and big banks.

  4. FDA Gives BMY Hep-C Drug 'Breakthrough' Status

    Bristol-Myers Squibb's (NYSE:BMY) investigational treatment for hepatitis C infection was awarded "breakthrough therapy designation" on Monday by U.S. drug regulator...

  5. AstraZeneca Says Generics to Dent '14 Profits

    AstraZeneca expects earnings to keep falling in 2014 as generic competition to its popular heartburn and ulcer drug Nexium takes a big bite out of U.S. profits from ...

  6. Investors Brace for Bear Market

    Many of the major equity market averages are down more than 5% from their recent highs and in a pullback. The concern now among many investors is that continued sell...

  7. Bristol -Myers 4Q Earnings Beat the Street

    Bristol-Myers Squibb (NYSE:BMY) reported a 21% drop in its fourth-quarter profit, a year after the drug company logged a significant tax benefit.Bristol-Myers said F...

‹ Prev12345Next ›
Source: Bristol-Myers Squibb on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL
{"cc_re__cc_re__cc_by_2_5": ["div>\n</div>\n<div class=\"ez-bottomContent ez-wideContent \">\n<div class=\"ez-attribution\">\n<div class=\"freebase-attribution\">\n<img width=\"61px\" style=\"float: left; border: 0;\" src=\"http://www.freebase.com/policies/freebase-cc-by-61x23.png\" height=\"23px\" alt=\"Freebase CC-BY\"><div style=\"font-size: x-small; margin-left: 70px; height: 30px; \"> Source: <a href=\"http://www.freebase.com/view/Bristol-Myers Squibb\">Bristol-Myers Squibb</a> on <a href=\"http://www.freebase.com/\">Freebase</a>, licensed under <a href=\"http://creativecommons.org/licenses/by/2.5/\">CC-BY</a>\n<br> Other content from <a href=\"http://en.wikipedia.org/wiki/Bristol-Myers Squibb\">Wikipedia</a>, licensed under the <a href=\"http://www.gnu.org/copyleft/fdl.html\">GFDL</a>\n</div>\n</div>\n</div>\n</div>\n<div class=\"ez-clearingDiv\"></div>\n</div></div>\n\t<div class=\"component\"> <!-- EZ Side Content --></div>\n</div></div>    \t\n\t\t<div id=\"section-footer-2\" class=\"footer-update\">\n\t<div class=\"encapsulate\">\n\t\t<div class=\"g-35\">\n\t\t\t<div class=\"g-7\">\n\t\t\t\t<div class=\"c c-bdr-4\">\n\t\t\t\t\t<h2 class=\"t"], "copyright__copyright__copyright": ["rket averages are down more than 5% from their recent highs and in a pullback.\u00a0The concern now among many investors is that continued sell...\n\n  7. Bristol -Myers 4Q Earnings Beat the Street\n\n    Bristol-Myers Squibb (NYSE:BMY) reported a 21% drop in its fourth-quarter profit, a year after the drug company logged a significant tax benefit.Bristol-Myers said F...\n\n\u2039 Prev12345Next \u203a\nSource: Bristol-Myers Squibb on Freebase, licensed under CC-BY\nOther content from Wikipedia, licensed under the GFDL", "rket averages are down more than 5% from their recent highs and in a pullback.\u00a0The concern now among many investors is that continued sell...\n\n  7. Bristol -Myers 4Q Earnings Beat the Street\n\n    Bristol-Myers Squibb (NYSE:BMY) reported a 21% drop in its fourth-quarter profit, a year after the drug company logged a significant tax benefit.Bristol-Myers said F...\n\n\u2039 Prev12345Next \u203a\nSource: Bristol-Myers Squibb on Freebase, licensed under CC-BY\nOther content from Wikipedia, licensed under the GFDL"]}